Market Overview

Why Marinus Pharmaceuticals Shares Spiked On Sage Therapeutics News

Why Marinus Pharmaceuticals Shares Spiked On Sage Therapeutics News
Related MRNS
41 Biggest Movers From Yesterday
48 Biggest Movers From Yesterday
Benzinga's Top Upgrades, Downgrades For August 6, 2018
Canaccord Previews Biotech Catalysts In The Second Half: Neurological Drugs In Focus
Detailed Research: Economic Perspectives on W.W. ... (GuruFocus)

Marinus Pharmaceuticals Inc (NASDAQ: MRNS) closed up 39.6 percent Thursday and continued another 3.9 percent pre-market Friday — but not on its own merits.

The stock moved mostly on sympathy for SAGE Therapeutics Inc (NASDAQ: SAGE), a biotech peer that released positive clinical data on its brexanolone treatment for major depressive disorder and subsequently surged 70 percent.

Street analysts expect the drug to advance to Phase 3 studies, eventually secure regulatory approval and potentially prove efficacious in treating Parkinson’s and essential tremor.

Sage’s progress was well interpreted by Marinus investors, who back a similar pipeline to treat postpartum depression and epilepsy. Marinus’ ganaxolone, a GABA modulator akin to SAGE-217, is in Phase 2 development for four separate trials.

At the time of publication, Marinus shares were set to open up 2.4 percent at $8.85, while Sage was up 1.7 percent at $158.99.

Related Links:

Hertz Moving In Sympathy With Avis Budget

5 Dry Bulk Shipping Stocks Moving In Sympathy With Diana Containerships Outsized Move

Hasbro, Mattel Just Proved That Sympathy Plays Don't Always Pay Off

Posted-In: ganaxolone SAGE-217Health Care Trading Ideas General Best of Benzinga


Related Articles (SAGE + MRNS)

View Comments and Join the Discussion!

Emboldened? Payday Lender CURO Group IPOs With Mulvaney Now In Charge Of CFPB

23 Stocks Moving In Friday's Pre-Market Session